spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  polycythemia vera 

 HSMN NewsFeed - 27 Apr 2026
Lilly to Acquire Ajax Therapeutics to Advance Outcomes for Patients with Myelofibrosis and Polycythemia Vera
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 10 May 2023
Sobi to Acquire CTI BioPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Mar 2022
Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2021
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology
Biopharmaceutical Gastroenterology Personnel
 HSMN NewsFeed - 2 Mar 2020
Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 17 Dec 2018
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Feb 2016
Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2015
Jakavi(R) (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients with Polycythemia Vera
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Feb 2015
Merganser Biotech Inc. Raises $28 Million in a Series A Financing to Develop Hepcidin Mimetic Peptides
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Mar 2014
Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2012
Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Mar 2011
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 May 2009
Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
Diagnostics Oncology
 HSMN NewsFeed - 12 Jul 2007
TargeGen, Inc. Closes $40M Series 'D' Financing Round
Biopharmaceuticals Venture Capital
Return to NewsFeed  
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!